Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer

Register of interests (PDF 168 KB)

Final draft guidance

Final draft guidance (PDF 219 KB)

Committee papers - ACM2 (PDF 1.25 MB)

Public committee slides - ACM2 (PDF 1.19 MB)

Final draft guidance - equality impact assessment (PDF 140 KB)

Draft guidance

Draft guidance (online commenting)

Draft guidance (PDF version) (PDF 266 KB)

Committee papers - ACM1 (PDF 8.75 MB)

Public committee slides - ACM1 (PDF 977 KB)

Final stakeholder list (PDF 167 KB)

Final scope (PDF 212 KB)

Draft scope and provisional stakeholder list comments table (post-referral) (PDF 192 KB)

Equality impact assessment (Scoping) (PDF 127 KB)

Consultation document - draft scope (PDF 231 KB)

Provisional Stakeholder List (post-referral) (PDF 166 KB)

Final appraisal document - TA693 (PDF 267 KB)

Committee papers - TA693 (PDF 12.44 MB)

Public committee slides - TA693 (PDF 1.66 MB)

Final appraisal document - managed access agreement - TA693 (PDF 425 KB)

Equality impact assessment - TA693 (PDF 151 KB)

Register of interests - TA693 (PDF 125 KB)

Final scope - TA693 (PDF 207 KB)

Final stakeholder list - TA693 (PDF 190 KB)

NICE's response to comments on the draft scope and provisional stakeholder list - TA693 (PDF 331 KB)